comparemela.com

Latest Breaking News On - Industry development agency of uzbekistan - Page 1 : comparemela.com

Uzbekistan replaces mandatory certification of local pharmaceuticals with post-marketing surveillance | Dentons

Effective July 1, 2022, the mandatory certification of medicines, medical devices and medical equipment of local production will be replaced with post-marketing surveillance. The local.

Rafarma Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of Uzbekistan

Rafarma Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of Uzbekistan

Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce its joint venture with the entity known as The Pharmaceutical Industry Development Agency of Uzbekistan which is essentially the Health Department of Uzbekistan. Together the two organizations will produce medicines for use by public health institutions in the Republic of Uzbekistan. This will entail the acquisition of real property (10 hectares in the established Innovative Scientific Production Pharmaceutical Cluster known as “Tashkent Pharma Park”) and construction of a physical plant on the premises. Projected costs are currently at $82,000,000. Both parties will be tasked with developing a timetable for project completion and implementation (projected time table 2021-2025). Rafarma will supply experts in their respective fields, oversee construction, and supply necessary equipment.

Rafarma Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Rafarma Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of . RAFARMA PHARMACEUTICALS INCJanuary 29, 2021 GMT Nicosia, Cyprus, Jan. 29, 2021 (GLOBE NEWSWIRE) Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce its joint venture with the entity known as The Pharmaceutical Industry Development Agency of Uzbekistan which is essentially the Health Department of Uzbekistan. Together the two organizations will produce medicines for use by public health institutions in the Republic of Uzbekistan. This will entail the acquisition of real property (10 hectares in the established Innovative Scientific Production Pharmaceutical Cluster known as “Tashkent Pharma Park”) and construction of a physical plant on the premises. Projected costs are currently at $82,000,000.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.